AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 ...

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib) is ...

Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.

AstraZeneca's Calquence hits the mark in the AMPLIFY combination trial in CLL, which could unlock a blockbuster opportunity for the BTK inhibitor.

AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non-small cell lung cancer, adding to its robust oncology portfolio. Despite ...

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

Astrazeneca Regulatory News. Live AZN RNS. Regulatory News Articles for Astrazeneca Plc Ord Shs $0.25Results from the AMPLIFY trial showed77% of patients treated with Calquence plus venetoclax and ...

Johnson Investment Counsel Inc. raised its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 4.4% during the first quarter, HoldingsChannel reports. The institutional investor ...